Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia

Blood Cancer Journal

Volumn 3, Issue 1, 2013, Pages

  Brandao, L N ^a   Winges, A ^a   Christoph, S ^a   Sather, S ^a   Migdall Wilson, J ^a   Schlegel, J ^a   McGranahan, A ^b   Gao, D ^a   Liang, X ^c   DeRyckere, D ^a   Graham, D K ^a  

^a Nutrition Obesity Research Center at the University of Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

MerTK; receptor tyrosine kinase; T cell leukemia; xenograft mouse model

Indexed keywords

CYTARABINE; ETOPOSIDE; MER RECEPTOR TYROSINE KINASE; MERCAPTOPURINE; METHYLCELLULOSE; PROTEIN TYROSINE KINASE; STAT PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84873638978     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.46     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010; 36: 277-285.
3. Landier W, Bhatia S. Cancer survivorship: a pediatric perspective. Oncologist 2008; 13: 1181-1192.
4. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-1582.
5. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21: 3613-3622.
6. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78: 1166-1172.
7. Raetz EA, Borowitz MJ, Devidas M, Hunger SP, Winick N, Camitta B et al. Outcomes of Children with First Marrow Relapse: Results from Children's Oncology Group (COG) Study AALL01P2. Blood (ASH Annual Meeting Abstracts) 2006; 108: 1871.
8. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 1994; 5: 647-657.
9. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008; 8: 327-336.
10. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007; 109: 1026-1033.
11. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996; 271: 30022-30027.
12. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995; 80: 661-670.
13. Balogh I, Hafizi S, Stenhoff J, Hansson K, Dahlback B. Analysis of Gas6 in human platelets and plasma. Arterioscler Thromb Vasc Biol 2005; 25: 1280-1286.
14. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993; 13: 4976-4985.
15. Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 2010; 14: 1073-1090.
16. Caberoy NB, Alvarado G, Bigcas JL, Li W. Galectin-3 is a new MerTK-specific eat-me signal. J Cell Physiol 2012; 227: 401-407.
17. Caberoy NB, Zhou Y, Li W. Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis. EMBO J 2010; 29: 3898-3910.
18. Newlaczyl AU, Yu LG. Galectin-3a jack-of-all-trades in cancer. Cancer Lett 2011; 313: 123-128.
19. Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H. Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Mol Cell Biol 1999; 19: 1171-1181.
20. Ling L, Kung HJ. Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol Cell Biol 1995; 15: 6582-6592.
21. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK et al. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res 2006; 12: 2662-2669.
22. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-143.
23. Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene 2006; 25: 6092-6100.
24. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 2010; 9: 1298-1307.
25. Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 2012 (e-pub ahead of print 13 August 2012; doi:10.1038/ onc.2012.355).
26. Migdall-Wilson J, Bates C, Schlegel J, Brandao L, Linger RM, DeRyckere D et al. Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. PLoS One 2012; 7: e31635.
27. Rogers AE, Le JP, Sather S, Pernu BM, Graham DK, Pierce AM et al. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene 2012; 31: 4171-4181.
28. Brandao L, Migdall-Wilson J, Eisenman K, Graham DK. TAM receptors in leukemia: expression, signaling, and therapeutic implications. Crit Rev Oncog 2011; 16: 47-63.
29. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008; 100: 35-83.
30. Demarchi F, Verardo R, Varnum B, Brancolini C, Schneider C. Gas6 anti-apoptotic signaling requires NF-kappa B activation. J Biol Chem 2001; 276: 31738-31744.
31. Estlin EJ. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine. Cancer Treat Rev 2001; 27: 351-363.
32. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309-1312.
33. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007; 131: 1124-1136.
34. Zong C, Yan R, August A, Darnell Jr JE, Hanafusa H. Unique signal transduction of Eyk: constitutive stimulation of the JAK-STAT pathway by an oncogenic receptor-type tyrosine kinase. EMBO J 1996; 15: 4515-4525.
35. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117(Pt 8): 1281-1283.
36. Shan X, Czar MJ, Bunnell SC, Liu P, Liu Y, Schwartzberg PL et al. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol 2000; 20: 6945-6957.